Total Payments
$115,109
2024 Payments
$32,320
Companies
21
Transactions
123
Payment Breakdown by Category
Consulting$70,509 (61.3%)
Other$18,160 (15.8%)
Travel$14,777 (12.8%)
Research$8,101 (7.0%)
Food & Beverage$3,542 (3.1%)
Education$21.19 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $70,509 | 29 | 61.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $16,760 | 5 | 14.6% |
| Travel and Lodging | $14,777 | 20 | 12.8% |
| Unspecified | $8,101 | 19 | 7.0% |
| Food and Beverage | $3,542 | 47 | 3.1% |
| Honoraria | $1,400 | 1 | 1.2% |
| Education | $21.19 | 2 | 0.0% |
Payments by Type
General
$107,008
104 transactions
Research
$8,101
19 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20,657 | 18 | $0 (2024) |
| Amryt Pharma Holdings Ltd | $16,915 | 7 | $0 (2023) |
| PFIZER INC. | $15,996 | 17 | $0 (2024) |
| Pierre Fabre Pharmaceuticals, Inc. | $12,593 | 9 | $0 (2024) |
| MITSUBISHI TANABE PHARMA AMERICA, INC. | $10,710 | 5 | $0 (2024) |
| LEO Pharma AS | $6,208 | 14 | $0 (2020) |
| NOBELPHARMA AMERICA, LLC | $4,562 | 5 | $0 (2023) |
| Novartis Pharma AG | $4,000 | 1 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $3,885 | 2 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,750 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32,320 | 29 | MITSUBISHI TANABE PHARMA AMERICA, INC. ($8,750) |
| 2023 | $9,442 | 11 | NOBELPHARMA AMERICA, LLC ($4,562) |
| 2022 | $13,644 | 10 | Amryt Pharma Holdings Ltd ($8,878) |
| 2021 | $18,760 | 7 | Amryt Pharma Holdings Ltd ($7,930) |
| 2020 | $10,731 | 7 | PFIZER INC. ($4,736) |
| 2019 | $4,892 | 13 | LEO Pharma AS ($4,442) |
| 2018 | $15,237 | 26 | Pierre Fabre Pharmaceuticals, Inc. ($6,697) |
| 2017 | $10,084 | 20 | PFIZER INC. ($6,930) |
All Payment Transactions
123 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $788.01 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | — | — | In-kind items and services | $52.03 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $49.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $34.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/09/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $24.99 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $249.66 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | RINVOQ (Biological) | — | In-kind items and services | $126.58 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis • Category: IMMUNOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | — | — | In-kind items and services | $69.68 | Research |
| Study: A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ||||||
| 10/25/2024 | Novartis Pharmaceuticals Corporation | VIJOICE (Drug) | Food and Beverage | In-kind items and services | $108.60 | General |
| Category: Oncology | ||||||
| 07/22/2024 | LEO Pharma Inc. | — | Consulting Fee | Cash or cash equivalent | $2,957.50 | General |
| 07/13/2024 | PFIZER INC. | LITFULO (Drug) | Food and Beverage | In-kind items and services | $103.06 | General |
| Category: IMMUNOLOGY | ||||||
| 07/12/2024 | MITSUBISHI TANABE PHARMA AMERICA, INC. | — | Consulting Fee | Cash or cash equivalent | $6,250.00 | General |
| 07/12/2024 | Novartis Pharmaceuticals Corporation | VIJOICE (Drug) | Food and Beverage | In-kind items and services | $53.51 | General |
| Category: Oncology | ||||||
| 07/11/2024 | LEO Pharma Inc. | — | Food and Beverage | In-kind items and services | $49.81 | General |
| 07/09/2024 | Novartis Pharma AG | PIQRAY (Drug) | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| Category: ONCOLOGY | ||||||
| 06/05/2024 | BioCryst Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $697.00 | General |
| 05/18/2024 | Novartis Pharmaceuticals Corporation | VIJOICE (Drug) | Food and Beverage | In-kind items and services | $49.81 | General |
| Category: Oncology | ||||||
| 05/11/2024 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Food and Beverage | In-kind items and services | $80.81 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 05/11/2024 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Food and Beverage | In-kind items and services | $71.71 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 05/10/2024 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Travel and Lodging | In-kind items and services | $752.13 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 05/10/2024 | Pierre Fabre Pharmaceuticals, Inc. | HEMANGEOL (Drug) | Food and Beverage | Cash or cash equivalent | $49.78 | General |
| Category: PEDIATRIC DERMATOLOGY | ||||||
| 04/19/2024 | Ipsen Biopharmaceuticals, Inc | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,080.00 | General |
| 04/12/2024 | Novartis Pharmaceuticals Corporation | VIJOICE (Drug) | Consulting Fee | Cash or cash equivalent | $3,800.00 | General |
| Category: Oncology | ||||||
| 03/14/2024 | Chiesi USA, Inc. | FILSUVEZ (Drug) | Consulting Fee | Cash or cash equivalent | $3,565.00 | General |
| Category: DERMATOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| TRALOKINUMAB VACCINE RESPONSE TIME | LEO Pharma AS | $1,535 | 5 |
| A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis | ABBVIE INC. | $1,421 | 9 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $674.89 | 2 |
About Dr. Joyce Teng, MD
Dr. Joyce Teng, MD is a Dermatology healthcare provider based in Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/14/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801850854.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joyce Teng, MD has received a total of $115,109 in payments from pharmaceutical and medical device companies, with $32,320 received in 2024. These payments were reported across 123 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($70,509).
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Pediatric Dermatology, Pediatric Dermatology
- Location Palo Alto, CA
- Active Since 04/14/2006
- Last Updated 04/16/2024
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1801850854
Products in Payments
- VIJOICE (Drug) $10,495
- EUCRISA (Drug) $6,920
- HEMANGEOL (Drug) $5,750
- HYFTOR (Drug) $4,562
- ENSTILAR (Drug) $4,506
- PIQRAY (Drug) $4,000
- DUPIXENT (Biological) $3,854
- FILSUVEZ (Drug) $3,565
- Orladeyo (Drug) $1,650
- Tremfya (Drug) $1,556
- RINVOQ (Biological) $1,299
- TALTZ (Drug) $710.88
- LITFULO (Drug) $103.06
- CIBINQO (Drug) $86.99
- Otezla (Drug) $76.01
- DUPIXENT DUPILUMAB INJECTION (Biological) $29.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Palo Alto
John Doux, M.d, M.D
Dermatology — Payments: $124,944
Dermatology $124,944
Shireen Guide, Md, MD
Dermatology — Payments: $79,371
Dermatology $79,371
Ilka Netravali, Md, MD
Dermatology — Payments: $28,025
Dermatology $28,025
Dr. Daniel Navi, M.d, M.D
Dermatology — Payments: $19,065
Dermatology $19,065
Dr. Thomas Hoffman, M.d, M.D
Dermatology — Payments: $17,860
Dermatology $17,860
Dr. Miguel Canales, M.d, M.D
Dermatology — Payments: $8,023
Dermatology $8,023